Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.
More than six years after winning approval, obesity drug Belviq has shown it’s heart-safe, but will that help it sell?
But with six months down and six to go, Humira is on track to keep its pharma TV ad crown for 2018 with spending well ahead of 2017.
Evoke Group has acquired Giant Creative Strategy, adding new geograhy and expertise in its aggressive growth strategy.
Bayer's latest campaign rolls with hometown America to show the company's broad array of products and connections to consumers.
Pfizer is taking heat from Congress and Wall Street analysts alike for its tepid response to Trump’s demand that it limit price hikes.
England’s National Health Service made its "final" offer to cover Vertex's cystic fibrosis drugs, but the company still isn't happy.
BMS already cut 107 positions at the facility earlier this year, and plans to close it by year's end.
J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.
Amid an industrywide debate over drug prices, top player J&J reports its net prices will fall between 4% and 6% in 2018.
